Briefing 03 · Executive Perspective · 7 min read
The economics of fragmentation in specialty commercialization.
Thesis
Fragmentation rarely shows up as a line item. It surfaces instead as adoption lag, abandonment, and the slow erosion of forecast credibility. Executives who treat alignment as an operating discipline — not a quarterly initiative — compound their launch economics for years.
"Alignment is not a meeting cadence. It is a measurable input to net revenue."
Fragmentation is the most expensive line item that never appears on a P&L. It shows up indirectly: as adoption that lags forecast by a quarter, as abandonment rates that no one fully owns, as a brand team and an access team building two versions of the same patient journey.
The compounding cost is forecast credibility. When the operating system is fragmented, leadership cannot tell whether a shortfall is a market signal or an internal one — and that uncertainty is what erodes the confidence of the board, the investor base, and the franchise itself.
The advantaged operators treat alignment as an operating discipline. They define it, measure it, and govern it with the same rigor they apply to clinical evidence and supply. Done well, it stops being a quarterly initiative and starts being a structural input to net revenue.
Bring this lens into a working session with your commercialization team.